Throughout 2024, the FDA issued new drug approvals and expanded treatment indications across various rheumatologic diseases.

Predictors of developing PsA among patients with arthralgia at risk for progression included a family history of psoriasis and specific ultrasound features.

HealthDay News — The frequency of medical board discipline for physician-spread misinformation is low, according to a study published online Nov. 12 in JAMA Network Open.

Utilizing the Dural Substitute Confetti technique during spinal cord stimulation trial implantation may reduce complications and shorten surgery time.

HealthDay News — Higher physical activity (PA) levels can increase life expectancy, according to a study published online Nov. 14 in the British Journal of Sports Medicine.

HealthDay News — Gabapentinoid use is associated with an increased risk for hip fractures, according to a study published online Nov. 13 in JAMA Network Open.

Investigators conducted a cross-sectional study to characterize xylazine use among adults being evaluated for substance use treatment for IMF or heroin.

Long-term treatment with anifrolumab significantly reduced the rate of organ damage compared with SOC among patients with SLE ...

Older patients with a higher comorbidity burden who have nongonococcal bacterial knee septic arthritis are at greater risk ...

Upadacitinib 15 mg plus a 26-week GC taper outperformed placebo in combination with a 52-week GC taper for the treatment of ...

The FDA approved Emrosi (minocycline hydrochloride extended-release capsules) for the treatment of inflammatory lesions of ...

Use of an implantable vagus nerve stimulation device was safe and effective for treating RA among patients who previously failed treatment with at least 1 b/tsDMARD.